Influenza A virus H5N1 vaccine - Antigen Express

Drug Profile

Influenza A virus H5N1 vaccine - Antigen Express

Alternative Names: AE 443p; AE AI vaccine; H5N1 virus vaccine - Antigen Express; H5N1 virus vaccine - Generex Biotechnology; Influenza peptide vaccines - Antigen Express; Pandemic influenza virus vaccine - Antigen Express/University of Rochester

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigen Express
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in Lebanon (Parenteral)
  • 28 Apr 2018 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)
  • 08 Feb 2017 Influenza A virus H5N1 vaccine - Antigen Express is available for licensing as of 08 Feb 2017. (Antigen Express pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top